Ko te Sinopharm BBIBP-CorV COVID-19 he kano kano mahi kore i hangaia mai i nga matūriki huaketo tipu-ahurea kaore he kaha pathogenic. Ko Sinopharm Holdings me Beijing Institute of Biological Products tenei kaitono kano kano ārai mate.